当前位置: X-MOL 学术J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties.
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2019-03-19 , DOI: 10.1021/acs.jmedchem.8b01971
Deyu Kong 1, 2 , Tao Xue 2 , Bin Guo 2 , Jianjun Cheng 3 , Shunyin Liu 1 , Jianhai Wei 1 , Zhengyu Lu 2 , Haoran Liu 2 , Guoqing Gong 4 , Tian Lan 4 , Wenhao Hu 1, 5 , Yushe Yang 2
Affiliation  

P2Y12 antagonists are widely used as antiplatelet agents for the prevention and treatment of arterial thrombosis. Based on the scaffold of a known P2Y12 antagonist AZD1283, a series of novel bicyclic pyridine derivatives were designed and synthesized. The cyclization of the ester substituent on the pyridine ring to the ortho-methyl group led to lactone analogues of AZD1283 that showed significantly enhanced metabolic stability in subsequent structure-pharmacokinetic relationship studies. The metabolic stability was further enhanced by adding a 4-methyl substituent to the piperidinyl moiety. Compound 58l displayed potent inhibition of platelet aggregation in vitro as well as antithrombotic efficacy in a rat ferric chloride model. Moreover, 58l showed a safety profile that was superior to what was observed for clopidogrel in a rat tail-bleeding model. These results support the further evaluation of compound 58l as a promising drug candidate.

中文翻译:

P2Y12拮抗剂乙基6-(4-((苯甲磺酰基)氨基甲酰基)哌啶-1-基)-5-氰基-2-甲基烟酸酯(AZD1283)的优化导致发现具有改善的类药物特性的口服抗血小板药。

P2Y12拮抗剂广泛用作预防和治疗动脉血栓形成的抗血小板药。基于已知的P2Y12拮抗剂AZD1283的支架,设计和合成了一系列新型的双环吡啶衍生物。吡啶环上的酯取代基与邻甲基的环化作用导致AZD1283的内酯类似物在随后的结构-药代动力学关系研究中显示出显着增强的代谢稳定性。通过向哌啶基部分添加4-甲基取代基进一步增强了代谢稳定性。在大鼠氯化铁模型中,化合物58l在体外显示出对血小板聚集的有效抑制以及抗血栓形成的功效。而且,58l显示出的安全性优于在大鼠尾巴出血模型中观察到的氯吡格雷的安全性。这些结果支持进一步评价化合物58l作为有前途的候选药物。
更新日期:2019-03-07
down
wechat
bug